Est. 2019
Est. 2019
Last Updated:
July 6, 2026
Parth Gaurav
Founder & CEO
.webp)
Quick answer: "Biotech website" isn't one thing. A TechBio platform sells defensibility to pharma BD. A clinical-stage company sells pipeline clarity to investors. A CDMO sells capacity and compliance to procurement. Six life-sciences sub-sectors have different buyers, different sales motions, and therefore different websites. Building all six the same way is the most common mistake.
By Parth Gaurav, Founder & CEO, Digi Hotshot. Last updated: June 25, 2026.
When a founder says "we need a biotech website," I've learned to ask one question back: what does the site actually have to do? Because the answer changes a lot depending on which corner of life sciences they sit in. A computational drug-discovery company and a clinical-stage therapeutics company both call themselves biotech. But one is selling a platform to pharma business development, and the other is selling a pipeline story to investors. Same word, different job. Different buyer, different sales motion, different thing to prove.
So treating "biotech" as one website template is a category error. You end up with a site that's vaguely about science and specifically about nothing. This is the companion piece to our deeper essay on the four-audience problem inside a single biotech site — that post zooms in on one company juggling investors, partners, talent, and patients at once. This one zooms out across the whole landscape, to show that the sub-sector you're in should decide what your site is for before you write a single headline.
Here's the map. Six segments, who each one is really talking to, the core job of the site, and the one mistake that segment makes most.
Now the detail. If you're in one of these, this is the part where you should feel a little seen.
Audience: pharma business development and senior technical hires. Job: prove the platform is real and defensible — not just clever.
TechBio companies — AI-driven drug discovery, computational platforms, foundation models for biology — have a specific trust problem. Every one of them claims an AI platform now. So the BD person at a pharma company isn't asking "is this cool." They're asking "is this real, and what stops a competitor from copying it next quarter." The site's job is to show the moat without giving away the IP: real platform architecture explained plainly, validation against known targets, named publications, and the team's technical credibility up front. The mistake is selling the science breathlessly while hiding the defensibility. If a reader can't tell what's proprietary, they assume nothing is.
Audience: investors and KOLs (key opinion leaders). Job: pipeline clarity and trial credibility, inside hard regulatory claim limits.
A clinical-stage company lives and dies by its pipeline. An investor lands on the site and wants, in about ten seconds, to understand: what programs, what indications, what phase, what's next, and when. That's a pipeline table — preferably one the marketing team can update the day a program advances, without a developer in the loop.
The constraint that makes this hard is regulatory. You can't make efficacy claims about an investigational drug. So the credibility has to come from structure and sourcing — trial registrations, mechanism explained carefully, publications, scientific advisors — not adjectives. The mistake I see most: a homepage that opens with a sweeping "reimagining medicine" vision statement and buries the actual pipeline three scrolls down. The pipeline is the story. Lead with it.
Audience: clinicians, lab directors, and payers. Job: evidence, validation studies, and a clear path to actually order the thing.
Diagnostics is an evidence sale. A clinician deciding whether to use your test wants the validation data — sensitivity, specificity, the studies behind it, peer-reviewed where possible. A payer wants to know reimbursement and clinical utility. And everyone wants to know the workflow: how do I order it, what's the turnaround, how do results come back.
So a diagnostics site needs a real evidence library and an obvious ordering path — two things that, surprisingly often, are both missing. The mistake here is a slick brand site with zero published data and no clear "how to order" page. You've made it beautiful and impossible to act on.
Audience: biotech teams procuring outsourced services. Job: prove capability, capacity, and compliance — fast.
This is the segment closest to our sweet spot, because it's a straight B2B services sale. A CDMO (contract development and manufacturing org) or CRO (contract research org) is selling to a procurement and technical-ops buyer who's comparing vendors on capability, capacity, lead time, and quality systems.
That buyer wants specifics. Which modalities? What scale can you run? What certifications — GMP, ISO, FDA inspection history? What's your on-time record? The site has to answer those without a sales call, because the buyer is doing most of the evaluation alone first. Gartner's research found B2B buyers spend only 17% of their evaluation time with suppliers — the rest is self-directed, much of it on your website. The mistake here is vague capability claims with no numbers and no certifications visible. "Comprehensive solutions" tells a procurement buyer nothing. A capability matrix and a quality-cert page tells them everything.
Audience: providers, payers, and employers. Job: product clarity, compliance signals, and a marketing team that can move fast.
Digital health and health-tech SaaS behave like B2B software — which is exactly the world we live in day to day. The buyer wants to understand the product quickly, see the integrations, and trust you with sensitive data. So the trust layer matters as much as the product story: HIPAA, SOC 2, and your security posture need to be visible, not buried in a footer link nobody clicks.
This segment also runs the most campaigns — different messaging for providers vs. payers vs. employers, plus events, webinars, and launches. So the website is a live marketing surface, not a brochure. The mistake is twofold: no obvious security/compliance signals, and a site so rigid that every landing page is a two-week engineering ticket. If marketing can't ship pages on its own, the campaigns slow to the speed of the dev queue.
Audience: clinicians, regulatory reviewers, and procurement. Job: regulatory status, clinical evidence, and a path for several stakeholders at once.
Medical devices carry the heaviest regulatory and multi-stakeholder load. The clinician wants clinical evidence and indications. Procurement wants pricing structure and integration. And every claim is gated by FDA status — 510(k) clearance, PMA approval, or investigational. That regulatory status isn't fine print; for many buyers it's the first thing they look for. Leaving it ambiguous reads as a red flag.
The mistake is a single-message device site that ignores the fact that three very different people have to say yes. A clinician, a regulatory reviewer, and a procurement lead don't read the same page the same way. The site has to route them, not flatten them into one generic audience.
Look at what those six jobs have in common. Pipeline tables that change when a program advances. Publication and validation libraries that grow monthly. Clinic or product pages that multiply as you expand. Security and certification pages that have to be accurate and visible. Campaign landing pages marketing needs to ship this week, not next quarter. Every one of those is a CMS problem plus a speed problem.
That's the case for Webflow in life sciences: pipelines, publications, and clinic libraries become structured CMS collections the marketing team updates directly, and new landing pages don't wait in an engineering queue. Forrester's 2024 study of Webflow put numbers on it — a 94% reduction in time to make major site changes and 332% three-year ROI. For a marketing team of two to five inside a regulated company, that autonomy is the difference between running campaigns and filing tickets.
We haven't built for a pure-biotech company yet, so I won't pretend otherwise. What we have done is run regulated, multi-location healthcare at scale. Sisu Clinic is a Webflow Enterprise build — 85+ pages across multiple countries, with the compliance-sensitive content and clinic structure that regulated life-sciences sites demand. It's adjacent proof, not a biotech claim. Across 50+ B2B Webflow builds since 2019, the structural patterns above are ones we've shipped many times in SaaS, fintech, and healthcare.
No. The buyer and the sales motion change by sub-sector. A TechBio platform sells defensibility to pharma BD; a CDMO sells capacity to procurement; a clinical-stage company sells pipeline clarity to investors. The page structure, evidence, and CTAs should follow that, so one template across all of them underperforms for each.
CDMO, CRO, and manufacturing services. They sell outsourced capability to a procurement and technical-ops buyer who compares vendors on capacity, certifications, and lead time — much like B2B SaaS. The site's job is to answer capability and compliance questions before a sales call, since buyers self-educate first.
You can't make efficacy claims about an investigational drug, so credibility comes from structure and sourcing, not adjectives — pipeline tables, trial registrations, mechanism explained carefully, publications, and named scientific advisors. The pipeline should lead the site, not sit below a vision statement.
Because most of these jobs are CMS plus speed problems. Pipelines, publications, validation studies, and clinic pages map cleanly to CMS collections a marketing team updates directly, and new campaign pages ship without an engineering ticket. Forrester measured a 94% reduction in time to make major site changes on Webflow.
Not a pure-biotech client yet — and we won't claim one. Our adjacent proof is regulated multi-location healthcare, including Sisu Clinic, an 85+ page Webflow Enterprise build across multiple countries, plus 50+ B2B Webflow builds since 2019 in SaaS, fintech, and healthcare.
Before you brief a designer or pick a template, figure out which of the six you actually are. The buyer decides the job, and the job decides the site. Get that wrong and you'll build something polished that converts no one.
If you want a second pair of eyes on where your site sits and what it's missing for your segment, we'll do a free audit — no pitch, just a clear read on the gaps. Cost depends on scope, so we start by understanding the work, not quoting a number. For a deeper read on what one biotech site has to juggle, the biotech website design guide goes section by section.
Last Updated:
July 6, 2026
Book a 30-minute discovery call. We'll discuss your current challenges and show you exactly how we can help.
Your competitors aren't stuck in developer queues. They're launching campaigns, testing messages, and capturing market share while you're waiting for simple updates.
Eliminate the bottlenecks. Give your marketing team the infrastructure they deserve—fast, autonomous, built to scale.
